Circulatory effects of the ultra-short-acting beta-1 adrenoceptor antagonist landiolol in critically ill patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025527

Enrollment

Registered

2022-04-28

Start date

2021-10-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48.9 I47.1

Interventions

Group 1: Transpulmonary thermodilution measurement (PiCCO® method) before and under Landiolol/Rapibloc® Administration (in the case of newly occurring AF), with the installation of the arterial thermi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Clinical indication for landiolol application as well as CVC system and PiCCO® catheter

Exclusion criteria

Exclusion criteria: pregnancy

Design outcomes

Primary

Measure	Time frame
The aim of this study is to use landiolol in everyday clinical practice with regard to the circulatory effects examine critically ill patients. The quantitative analysis of the means of a extended cardiovascular monitoring procedure (transpulmonary thermodilution with integrated pulse contour analysis, PiCCO® method) obtained circulatory parameters should be assess effects and safety.	—

Countries

Germany

Contacts

Public ContactSven Menke

Universität Witten/Herdecke

sven.menke@uni-wh.de0160 97749376

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026